congresses-banner

The content contained is subject

PublicationView

Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Tumor-agnostic
A long-term phase 4 study to evaluate the risk of idiosyncratic hepatotoxicity associated with pexidartinib treatment
Arun S. Singh
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Tumor-agnostic
Health-related quality of life from a phase 4 global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib
Jayesh Desai
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Tumor-agnostic
Pexidartinib upfront in a case study of tenosynovial giant cell tumor: Proof of concept for a treatment paradigm shift
Emanuela Palmerini
Oral
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Tumor-agnostic
Pexidartinib use in patients with tenosynovial giant cell tumor: An analysis of the phase III randomized ENLIVEN clinical trial according to surgical history
John H. Healey
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Tumor-agnostic
Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor (TGCT)
Dong Dai
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Tumor-agnostic
Tumor response and regrowth in relation to clinical events among pexidartinib-treated patients in the phase 3 ENLIVEN trial
Jayesh Desai

footer